Journal
NEUROSIGNALS
Volume 16, Issue 1, Pages 11-18Publisher
KARGER
DOI: 10.1159/000109754
Keywords
biomarkers; Alzheimer's disease; diagnosis; neurodegenerative disease
Funding
- NCRR NIH HHS [P41 RR002305-255549, P41 RR002305, P41 RR002305-236875, P41 RR002305-246021] Funding Source: Medline
- NIA NIH HHS [AG10124, R01 AG014971-09, U19 AG010483, R01 AG014971-08, R01 AG014971, P30 AG010124] Funding Source: Medline
- NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR002305] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE ON AGING [P30AG010124, U19AG010483, R01AG014971] Funding Source: NIH RePORTER
Ask authors/readers for more resources
The increasing prevalence of Alzheimer's disease and the devastating consequences of late- life dementia motivates the drive to develop diagnostic biomarkers to reliably identify the pathology associated with this disorder. Strategies to accomplish this include the detection of altered levels of tau and amyloid in cerebrospinal fluid, the use of structural MRI to identify disease- specific patterns of regional atrophy and MRI T-1 rho to detect disease- related macromolecular protein aggregation, and the direct imaging of amyloid deposits using positron emission tomography and single photon emission computerized tomography. Success will facilitate the ability to reliably diagnose Alzheimer's disease while the symptoms of brain failure are mild and may provide objective measures of disease- modifying treatment efficacy. Copyright (c) 2008 S. Karger AG, Basel.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
